Holen Sie sich die Stockscreener-App
1.06
6.74%
0.0669
Handel nachbörslich:
1.04
-0.02
-1.89%
Schlusskurs vom Vortag:
$0.9931
Offen:
$0.99
24-Stunden-Volumen:
577.72K
Relative Volume:
1.69
Marktkapitalisierung:
$23.70M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-16.51M
KGV:
-0.7836
EPS:
-1.3528
Netto-Cashflow:
$-15.68M
1W Leistung:
-4.50%
1M Leistung:
-26.90%
6M Leistung:
-49.52%
1J Leistung:
-65.58%
1-Tages-Spanne:
$0.98
$1.16
1-Wochen-Bereich:
$0.9174
$1.16
52-Wochen-Spanne:
$0.9174
$8.94
Medicus Pharma Ltd Stock (MDCX) Company Profile
Firmenname
Medicus Pharma Ltd
Sektor
Telefon
610-540-7515
Adresse
300 CONSHOHOCKEN STATE RD., W. CONSHOHOCKEN
Compare MDCX vs LLY, JNJ, ABBV, AZN, NVS
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MDCX
Medicus Pharma Ltd
|
1.06 | 22.21M | 0 | -16.51M | -15.68M | -1.3528 |
|
LLY
Lilly Eli Co
|
1,040.00 | 929.27B | 65.18B | 20.64B | 6.44B | 22.96 |
|
JNJ
Johnson Johnson
|
243.45 | 589.19B | 94.19B | 26.80B | 19.70B | 11.05 |
|
ABBV
Abbvie Inc
|
231.50 | 402.08B | 61.16B | 4.20B | 19.68B | 2.3671 |
|
AZN
Astrazeneca Plc
|
205.55 | 317.06B | 58.80B | 10.24B | 8.98B | 3.2788 |
|
NVS
Novartis Ag Adr
|
163.10 | 307.56B | 54.72B | 14.02B | 15.32B | 7.1855 |
Medicus Pharma Ltd Aktie (MDCX) Neueste Nachrichten
Does Medicus Pharma Ltd. Equity Warrant have declining or rising EPS2025 Support & Resistance & Fast Entry High Yield Stock Tips - mfd.ru
Medicus Pharma’s Teverelix Phase 2b trial cleared by FDAICYMI - Proactive financial news
Can Medicus Pharma Ltd. Equity Warrant ride the EV waveWeekly Market Outlook & Short-Term High Return Ideas - mfd.ru
Is Medicus Pharma Ltd. Equity Warrant a speculative investmentGold Moves & Low Volatility Stock Suggestions - mfd.ru
Will Medicus Pharma Ltd. Equity Warrant benefit from rising consumer demand2025 Top Decliners & Comprehensive Market Scan Insights - mfd.ru
Why Medicus Pharma Ltd. stock attracts high net worth investorsDollar Strength & High Win Rate Trade Alerts - mfd.ru
Aug Decliners: Is Medicus Pharma Ltd Equity Warrant likely to announce a buybackMarket Trend Review & Short-Term High Return Strategies - baoquankhu1.vn
Medicus Pharma Ltd. Enters Into $5.1 Million Warrant Inducement - Asbury Park Press
Analyst Calls: Can Medicus Pharma Ltd stock outperform in a bear marketSell Signal & AI Enhanced Trading Alerts - baoquankhu1.vn
Will Medicus Pharma Ltd. (N460) stock sustain bullish trend into 20252025 AllTime Highs & Short-Term Trading Opportunity Alerts - mfd.ru
Medicus Pharma cleared to launch Phase 2b Teverelix study in Prostate Cancer - Proactive financial news
Medicus Pharma Partners With Gorlin Syndrome Alliance to Expand Access to SKINJECT - MSN
Medicus Pharma on Bloomberg World - Weatherford Democrat
Is Medicus Pharma Ltd. Equity Warrant forming bullish engulfing patternsMarket Activity Recap & Weekly Setup with ROI Potential - mfd.ru
Is Medicus Pharma Ltd. Equity Warrant affected by consumer sentimentTrade Entry Summary & Fast Momentum Entry Tips - mfd.ru
Medicus Pharma Marks Nasdaq Anniversary With Opening Bell Ceremony - PhillyBurbs
Can Medicus Pharma Ltd. expand its profit margins2025 Analyst Calls & Long-Term Investment Growth Plans - mfd.ru
What are Medicus Pharma Ltd. Equity Warrant’s technical support levels2025 Breakouts & Breakdowns & AI Powered Trade Plan Recommendations - mfd.ru
FDA clears Medicus Pharma’s prostate cancer drug for phase 2b trial By Investing.com - Investing.com South Africa
FDA clears Medicus Pharma’s prostate cancer drug for phase 2b trial - Investing.com Nigeria
New to The Street Signs Six-Part Media Series Featuring Medicus Pharma Ltd. - USA Today
Small cap wrap: Medicus Pharma, 1911 Gold, NanoViricides, Nextech3D.ai, NextSource Materials… - Proactive financial news
Medicus Pharma Wins FDA Go-Ahead for Phase 2b Teverelix Trial in High-Risk Prostate Cancer - TipRanks
Medicus Pharma receives FDA clearance to proceed with Phase 2b prostate cancer study - Proactive financial news
Medicus Pharma Receives FDA 'Study May Proceed” Clearance For Teverelix® Phase 2b Study in Advanced Prostate Cancer Patients with High Cardiovascular Risk - The Manila Times
FDA clears trial of Teverelix for prostate cancer with high heart risk - Stock Titan
How Medicus Pharma Ltd. Equity Warrant stock reacts to inflationary pressures2025 Support & Resistance & Momentum Based Trading Ideas - mfd.ru
Trade Report: Can Medicus Pharma Ltd expand its profit marginsJuly 2025 Review & Risk Managed Trade Strategies - baoquankhu1.vn
Medicus Pharma Ltd. Announces Engagement With Reliant AI to Develop Artificial Intelligence (AI) Driven Clinical Data Analytics Platform - The Marion Star
Merger Talk: Can Medicus Pharma Ltd expand its profit marginsTrade Entry Summary & Consistent Profit Focused Trading Strategies - baoquankhu1.vn
Medicus Pharma Reports Q3 Loss Amid Strategic Growth - MSN
Finanzdaten der Medicus Pharma Ltd-Aktie (MDCX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Medicus Pharma Ltd-Aktie (MDCX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| VELOCITY FUND PARTNERS, LP | 10% Owner |
May 20 '25 |
Sale |
7.72 |
75,000 |
578,940 |
3,248,741 |
0.40%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):